Market Size of Pleural Effusions Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pleural Effusions Treatment Market Analysis
The Pleural Effusions Treatment Market is poised to grow at a CAGR of 4.7% over the forecast period (2022 - 2027).
The Covid-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities. An increasing number of congestive heart failure, cancer, pneumonia, and pulmonary embolism during the pandemic increased the risk of pleural effusions among patients. Various research was conducted to find a correlation between Covid-19 infection and pleural effusion. For instance, the article 'Prevalence and Clinical Outcomes of Pleural Effusion in Covid-19 Patients: A Systematic Review and Meta-Analysis' published in January 2022 showed that pleural effusion is related to the risk and prognosis of Covid-19 disease. And pleural effusion can be used as a prognostic indicator to assess the likelihood of poorer outcomes in Covid-19 patients; as a result, the researchers of the above-mentioned research article advised that hospitalized Covid-19 patients with pleural effusion be handled promptly. These research and studies are predicted to have increased the demand for the treatment of pleural effusions during the pandemic. Thus, the pandemic is anticipated to show a considerable impact on the market studied.
Factors such as the increasing prevalence of pleural effusions and significant progress in the management of pleural effusions globally are expected to positively impact the market growth.
The rising prevalence of pleural effusions (PE) is one of the major factors that contribute to market growth. For instance, an article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people. This burden of the condition is creating demand for the availability of pleural effusion treatments globally. And it is expected to fuel the market growth during the analysis period.
Furthermore, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For instance, in September 2021, BDR Pharma launched BIAPENEM to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections. Biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid). Such advancements are expected to drive the market to grow in the future.
Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the partial success rate of treatments is anticipated to hinder market growth.
Pleural Effusions Treatment Industry Segmentation
As per the scope of this report, the pleural effusion treatment is generally the therapy of pleural effusion, i.e. an abnormal collection of fluid between the thin layers of tissue (pleura) lining the lung and the wall of the chest cavity. The Pleural Effusions Treatment Market is segmented by Disease Type (Transudative and Exudative), End User (Hospitals, Ambulatory Clinics and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Disease Type | |
| Transudative | |
| Exudative |
| By End User | |
| Hospitals | |
| Ambulatory Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Pleural Effusions Treatment Market Size Summary
The pleural effusions treatment market is expected to experience steady growth over the forecast period, driven by an increasing prevalence of pleural effusions and advancements in treatment options. The COVID-19 pandemic has significantly impacted the market, as it highlighted the correlation between pleural effusions and various health conditions, such as congestive heart failure, cancer, and pneumonia. This has led to a heightened demand for pleural effusion treatments. The market is further bolstered by ongoing research and development activities, including product launches and strategic collaborations, which are expected to enhance treatment availability and efficacy. Despite these positive trends, the market faces challenges due to the partial success rate of existing treatments, which may hinder growth.
Regionally, North America is anticipated to dominate the pleural effusions treatment market, with the United States leading due to increased healthcare expenditure and a rising prevalence of heart diseases. The aging population and the high burden of cardiovascular diseases in the United States are significant factors contributing to the market's expansion. The market is moderately competitive, with key players such as B. Braun SE, Becton, Dickinson and Company, and others holding substantial market shares. These companies are actively involved in clinical trials and research to improve treatment outcomes, which is expected to drive market growth in the coming years.
Pleural Effusions Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Pleural Effusions
-
1.2.2 Significant Progress in the Management of Pleural Effusions
-
-
1.3 Market Restraints
-
1.3.1 Partial Success Rate of Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Disease Type
-
2.1.1 Transudative
-
2.1.2 Exudative
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Ambulatory Clinics
-
2.2.3 Other End Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Pleural Effusions Treatment Market Size FAQs
What is the current Pleural Effusions Treatment Market size?
The Pleural Effusions Treatment Market is projected to register a CAGR of 4.70% during the forecast period (2024-2029)
Who are the key players in Pleural Effusions Treatment Market?
Becton, Dickinson and Company , Biometrix , Redax , Grena and B. Braun Melsungen are the major companies operating in the Pleural Effusions Treatment Market.
